Article

Improved prediction of the response duration to MAPK inhibitors in patients with advanced melanoma using baseline genomic data and machine learning algorithms

2023-12-09

Abstract excerpt

<h4>Purpose</h4> Baseline genomic data have not demonstrated significant value for predicting the response to MAPK inhibitors (MAPKi) in patients with BRAF V600 -mutated melanoma. We used machine learning algorithms and pre-processed genomic data to test whether they could contain useful information to improve the progression-free survival (PFS) prediction. <h4>Experimental design</h4> This exploratory analysis co...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6574b68e-29fa-526f-a5c4-02ee8592b826
DOI: 10.1101/2023.12.07.23299389

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Improved prediction of the response duration to MAPK inhibitors in patients with advanced melanoma using baseline genomic data and machine learning algorithmsDOI 10.1101/2023.12.07.23299389Read

Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in <i>BRAF</i> -Mutant MelanomaSemantic proximity Read

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.Semantic proximity Read

Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary MelanomasSemantic proximity Read

Primary tumor characteristics and next-generation sequencing mutations as biomarkers for melanoma immunotherapy response.Semantic proximity Read

A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021.Semantic proximity Read

Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapySemantic proximity Read

Treatment algorithms in stage IV melanoma.Semantic proximity Read

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.Semantic proximity Read

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF V600-mutated Metastatic MelanomaSemantic proximity Read

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials.Semantic proximity Read

A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer typesSemantic proximity Read

Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed MelanomasSemantic proximity Read